Ambeed.cn

首页 / 抑制剂/激动剂 / 膜转运蛋白 / ATPase / Esomeprazole

Esomeprazole {[allProObj[0].p_purity_real_show]}

货号:A388173 同义名: (S)-Omeprazole;(-)-Omeprazole Ambeed 开学季,买赠积分,赢豪礼

Esomeprazole is a proton-pump inhibitor which reduces stomach acid.

Esomeprazole 化学结构 CAS号:119141-88-7
Esomeprazole 化学结构
CAS号:119141-88-7
Esomeprazole 3D分子结构
CAS号:119141-88-7
Esomeprazole 化学结构 CAS号:119141-88-7
Esomeprazole 3D分子结构 CAS号:119141-88-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Esomeprazole 纯度/质量文件 产品仅供科研

货号:A388173 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 ATPase 其他靶点 纯度
(-)-Blebbistatin {[allProObj[0].p_purity_real_show]}
PF 03716556 ++++

H+/K+-ATPase, pIC50: ~6.5

{[allProObj[0].p_purity_real_show]}
Esomeprazole sodium {[allProObj[0].p_purity_real_show]}
BTB06584 {[allProObj[0].p_purity_real_show]}
Ciclopirox {[allProObj[0].p_purity_real_show]}
CB-5083 ++++

p97 AAA ATPase, IC50: 11 nM

{[allProObj[0].p_purity_real_show]}
Ciclopirox olamine {[allProObj[0].p_purity_real_show]}
Brefeldin A +++

ATPase (HCT 116), IC50: 0.2 μM

{[allProObj[0].p_purity_real_show]}
Oligomycin A {[allProObj[0].p_purity_real_show]}
Sodium orthovanadate +++

(Na,K)-ATPase, IC50: 40 nM

{[allProObj[0].p_purity_real_show]}
Golgicide A {[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Esomeprazole 生物活性

描述 Proton pump inhibitors (PPIs) are one of the most prescribed class of drugs today and are used for patients with an array of gastroenterological conditions that include gastroesophageal reflux, peptic ulcer disease, Helicobacter pylori infection, and Barrett's esophagus[3]. Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single isomer. Esomeprazole provided better control of intragastric pH than omeprazole, lansoprazole and pantoprazole in trials conducted in patients with gastro-oesophageal reflux disease (GORD) or healthy volunteers (n = 20 to 115). In 2 large randomised, double-blind multicentre trials, esomeprazole 20 and/or 40mg for 8 weeks produced higher healing rates of erosive oesophagitis and better symptom control than omeprazole 20 mg in patients with GORD[4].

Esomeprazole 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT01205230 Cancer Phase 4 Completed - United States, New Jersey ... 展开 >> GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, South Carolina GSK Investigational Site Greenville, South Carolina, United States, 29605 收起 <<
NCT00352261 Barrett's Esophagus Phase 4 Completed - United States, Arizona ... 展开 >> Research Site Phoenix, Arizona, United States Research Site Tucson, Arizona, United States United States, Illinois Research Site North Chicago, Illinois, United States United States, Minnesota Research Site Rochester, Minnesota, United States United States, Missouri Research Site Kansas City, Missouri, United States Research SIte Springfield, Missouri, United States United States, Montana Research Site Butte, Montana, United States United States, Ohio Research Site Cleveland, Ohio, United States United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States United States, Tennessee Research Site Knoxville, Tennessee, United States United States, Texas Research Site Dallas, Texas, United States United States, Virginia Research Site Norfolk, Virginia, United States 收起 <<
NCT01205230 - Completed - -

Esomeprazole 参考文献

[1]Shin JM, Munson K, et al. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Arch. 2009 Jan;457(3):609-22.

[2]Lind T, Rydberg L, et al. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2000 Jul;14(7):861-7.

[3]Brisebois S, Merati A, Giliberto JP. Proton pump inhibitors: Review of reported risks and controversies. Laryngoscope Investig Otolaryngol. 2018 Oct 19;3(6):457-462. doi: 10.1002/lio2.187. PMID: 30599030; PMCID: PMC6302736.

[4]Esomeprazole

Esomeprazole 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.90mL

0.58mL

0.29mL

14.48mL

2.90mL

1.45mL

28.95mL

5.79mL

2.90mL

Esomeprazole 技术信息

CAS号119141-88-7
分子式C17H19N3O3S
分子量 345.42
别名 (S)-Omeprazole;(-)-Omeprazole;(–)-Omeprazole
运输蓝冰
存储条件

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 120 mg/mL(347.4 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。